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Genetic variants of interleukin-3 (IL-3), a well-studied cytokine, may have a role in the pathophysiology of rheu-
matoid arthritis (RA); but reports on this association sometimes conflict. A case-control study was designed to
investigate association between RA and a single-nucleotide polymorphism (SNP) in the IL-3 promoter region.
Comparison of cases of RA versus control individuals yielded a x2 value of 14.28 ( ), with a genotypePp .0002
odds ratio of 2.24 (95% confidence interval [95%CI] 1.44–3.49). When female cases with earlier onset were
compared with female control individuals, the SNP revealed an even more significant correlation, with 2x p
( ) and a genotype odds ratio of 7.27 (95%CI 2.80–18.89). The stronger association that we21.75 Pp .000004
observed in this clinically distinct subgroup (females with early onset), within a region where linkage disequilibrium
was not significantly extended, suggested that the genuine RA locus should locate either within or close to the IL-
3 gene. Combined genotype data on SNPs on eight other candidate genes were combined with our IL-3 results, to
estimate relationships between pairs of loci and RA, by maximum-likelihood analysis. The utility of combining the
genotype data in this way to identify possible contributions of various genes to this disease is discussed.
Introduction
Rheumatoid arthritis (RA [MIM 180300]) is one of the
common clinical entities with complex genetic etiology;
in fact, numerous genes are likely to be associated with
this disease (Selden et al. 1999). Two independent sib-
pair linkage analyses have reported multiple loci as can-
didates (Cornelis et al. 1998; Shiozawa et al. 1998), but
association studies involving those genes have been in-
conclusive except in the case of human leukocyte antigen
(HLA) class II (Nepom 1998).
The cytokine IL-3 represents a potential candidate for
RA because it affects differentiation, proliferation, and
function of three hematopoietic lineages in bone marrow
and also has important physiological functions with re-
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gard to mature myeloid cells in the peripheral system
(Harant and Lindley 1998). The human IL-3 gene lies
on chromosome 5q23-31, together with genes encoding
granulocyte monocyte-colony–stimulating factor (GM-
CSF), IL-4, IL-5, IL-9, macrophage colony–stimulating
factor, and several other genes related to the immune
system. The GM-CSF gene is only 9 kb distant from IL-
3 (Yang et al. 1988). Therefore, it seemed interesting to
investigate the possible association between RA and poly-
morphisms in the region containing the IL-3 gene, not
only to detect potential association between the gene itself
and the disease but also to evaluate other genes in this
region to determine their possible contributions to RA,
if considerable linkage disequilibrium (LD) exists among
them.
Although previous reports on association between IL-
3 and RA were not conclusive (Firestein et al. 1988;
Waalen et al. 1992; Heller et al. 1997; Levesque et al.
1998), we designed a case-control association study, us-
ing an a single-nucleotide polymorphism (SNP) in the
promoter region of the IL-3 gene, and we evaluated the
range of LD by genotyping two other SNPs close to the
promoter SNP. In addition, the functional consequence
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Figure 1 Map of IL-3 and GM-CSF genes, showing locations
of the three SNPs genotyped.
that the promoter SNP had on gene expression was
investigated.
Identification of genes associated with complex ge-
netic traits is often very difficult because their individual
contributions are likely to be small; optimization of data
seems indispensable. Therefore, to estimate the com-
binatorial effect of pairs of loci by the maximum-like-
lihood method, we also genotyped our subjects for SNPs
present in eight other candidate genes and investigated
relationships between each of them and the IL-3 poly-
morphism, with regard to RA susceptibility.
Subjects and Methods
Subjects
Cases and controls were recruited through several
medical institutes in Japan. All subjects were Japanese
and consented to participate in the study according to
the process approved by the Ethical Committee at the
SNP Research Center, The Institute of Physical and
Chemical Research (RIKEN), Tokyo. All cases met the
American Rheumatism Association’s revised criteria for
the classification of RA (Arnett et al. 1988). A total of
254 cases and 881 controls were enrolled.
SNPs
Three SNPs in the IL-3 vicinity were genotyped. These
sites are at nt 16 (TrC) in the 5′ flanking (promoter)
region of the IL-3 gene, at nt 131 (TrC) of exon 1 of
the IL-3 gene, and at nt 23 (CrT) of exon 4 of the GM-
CSF gene; these sites match bases 4247, 4393, and
19375 on the GenBank sequence AC004511.1 (gi
3002474). Hereafter, we will refer to them as “rIL-3-
16,” “cIL-3-131,” and “cGM-CSF-23,” respectively (fig.
1). cIL-3-131 substitutes the 8th serine for proline in the
IL-3 product (Jeong et al. 1998), and cGM-CSF-23 sub-
stitutes the 117th threonine for isoleucine in the GM-
CSF protein (Yamada et al. 2000). SNPs on eight other
genes were also assessed for association with RA, to
evaluate possible relationships to IL-3. The eight genes
were those for metalloproteinase 2 (MMP2), tumor ne-
crosis–factor receptor 1 (TNFR1), signal transducer and
activator of transcription-6 (STAT6), interleukin-15 (IL-
15), interleukin-1b (IL-1b), CD44, interleukin-4 recep-
tor a (IL-4a), and tissue inhibitor of metalloproteinase
1 (TIMP1). The accession number of the GenBank ref-
erence sequence, the location on the sequence, the bases
potentially substituted in the eight SNPs, as well as the
SNPs in IL-3 and in GM-CSF were summarized in table
1. These SNPs were identified by the same procedure
that we had used earlier for cGM-CSF-23 (Yamada et
al. 2000).
Genotyping of SNPs
DNA samples were extracted from whole peripheral
blood by standard methods and were genotyped for
SNPs by PCR–allele-specific oligonucleotide hybridiza-
tion (PCR-ASO). For that procedure, 10 segments, one
containing two SNPs on the IL-3 gene and one from
each of the other nine genes, were amplified by PCR
using the primers listed in table 2. ASO hybridizations
were performed as follows: Each PCR product contain-
ing an SNP locus was transferred to a BIODYNE (B)
membrane (PALL), was chemically denatured, and was
fixed by UV light. Each allele-specific genotyping primer
was labeled with [32P]-ATP by polynucleotide kinase.
Membranes were prehybridized in hybridization solu-
tion for 2 h at 35C; then they were hybridized with
genotyping primers for 4 h at 35C; and then they were
washed in 6 # SSC under the conditions described in
table 2.
Typing of HLA-DRB1
All cases were typed for HLA-DRB1, with the HLA-
DRB BigDye Terminator Sequencing-Based Typing Kit
(PE Biosystems).
Assay of IL-3 Promoter
We performed luciferase assays to evaluate whether
the SNP at the rIL-3-16 locus influences promoter func-
tion, using two promoter segments of different lengths.
The longer segment ranged from base 357 in the 5′
flanking region to base 55 in exon 1, and the shorter
one ranged from base 59 in the 5′ flanking region to
base 55 in exon 1. A target segment corresponding to
each allele was amplified by PCR using genotype-known
genomic DNAs as templates; primers for this procedure
were, for the longer segment, 5′-AAGATCTAGGGTA-
GTCCAGGTGATGGCA-3′ and 5′-AAAGCTTCATGT-
TTGGATCGGCAGGAGG-3′ and, for the shorter seg-
ment, 5′-TTAAGATCTCGGGGTTGTGGGCACCTTG-
CTG-3′ and 5′-AAAGCTTCATGTTTGGATCGGCAG-
GAGG-3′. PCR products were digested with BglII and
HindIII and were cloned into Photinus luciferase re-
porter plasmid pGVB2 (Nippon Gene). Cloned DNAs
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Table 1
Genotyped SNPs
GENE CONTAINING SNP(S)
GENBANK REFERENCE SEQUENCE BASE
Accession Number
Location
of SNP Major Allele Minor Allele
IL-3 (rIL-3-16) AC004511.1 (gi 3002474) 4247 T C
IL-3 (cIL-3-131) AC004511.1 (gi 3002474) 4393 T C
GM-CSF (cGM-CSF-23) AC004511.1 (gi 3002474) 19375 C T
MMP2 U96098.1 (gi 2459743) 932 C T
TNFR1 AC006057.1 (gi 4731048) 34201 A G
STAT6 AF067575.1 (gi 3789866) 4671 G A
IL-15 AF038163.1 (gi 2708695) 560 T A
IL-1b X04500.1 (gi 33788) 1423 C T
CD44 L05423.1 (gi 337955) 674 C T
IL-4Ra AC004525.1 (gi 3219333) 94272 G A
TIMP1 D11139.1 (gi 220124) 600 G C
were validated by dye-terminator DNA sequencing. The
plasmid DNAs were transfected into Jurkat cells, by Su-
perfectant transfection reagent (QIAGEN). Transfected
cells were stimulated with 40 ng of phorbol myristate
acetate/ml and 4 mg of ionomycin/ml, and luciferase ac-
tivities were measured 48 h later by a chemiluminescence
assay (PicaGene Dual SeaPansy Assay System kit; Toyo
Ink). Three independent experiments of transfection
were performed.
Statistical Analysis
Cases were subdivided by sex, age at onset (!55 years
and 55), rheumatoid-factor status, history of ortho-
pedic intervention for RA-related arthropathy, and
RA-susceptible HLA-DRB1 status. Controls were also
subdivided by sex and were adjusted for sex and for age
at sampling (i.e., !30, 30–39, 40–49, 50–59, or 60
years), to fit the case-group distribution. All cases or
subgroups of cases were compared with all controls or
corresponding subgroups of controls, respectively, with
adjustment for sex and age. Alternative hypotheses and
null hypotheses for association between cases and con-
trols were evaluated by x2 tests; in each case, the odds
ratio and 95% confidence interval (95%CI) were cal-
culated by Woolf’s method. Haplotype frequencies for
pairs of alleles, as well as x2 values for allele associations,
were estimated by the Estimating Haplotype-frequencies
software program (Terwilliger and Ott 1994; Web Re-
sources for Genetic Linkage Analysis [Rockefeller Uni-
versity]). LD coefficients were calculated′D p D/Dmax
(Devlin and Risch 1995). Hardy-Weinberg equilibrium
of alleles at individual loci was assessed by x2 statistics
(Nielsen et al. 1999).
Estimation of Combinatorial Effect of Two Loci, by Use
of Genotype Data
Genotype data on eight SNPs in 91 cases and in 91
controls were combined with data on rIL-3-16. The most
likely pattern of combinatorial genetic contribution of
any two loci was estimated by the maximum-likelihood
method (Appendix). Genotype relative risk was defined
against the genotype that consisted of homozygotes of
nonsusceptibility alleles from both SNPs. The variables
used to define a relative risk of combined genotypes were
designed such that the relative risk for heterozygotes was
either equal to or the square root of the relative risk for
homozygotes of susceptibility alleles from both SNPs,
or 1, as modeled by Risch and Merikangas (1996). The
model represented 10 patterns of distribution of the ge-
notype relative risk, with variation of the relative risk
of heterozygotes compared with of homozygotes. One
of the 10 patterns was independent, which meant that
two loci possessed disease-susceptible alleles on their
own and that those alleles increased the risk of RA with-
out mutual interaction The other nine patterns repre-
sented combinatorial effects on genotype risk. LOD
scores were calculated, for comparison with a hypothesis
that no association was present for either SNP; we cal-
culated the difference between the highest LOD score
among the nine combinatorial patterns and the LOD
score for the independent pattern, to test the likelihood
of the combinatorial pattern against the independent
pattern. If an independent relationship to RA was esti-
mated as being most likely, then subgrouping of the test
population by genotype status of two SNPs was consid-
ered inappropriate for testing of associations with the
disease; on the other hand, if a combinatorial rather than
an independent pattern was estimated as being most
likely for two SNPs with a difference between two LOD
scores, then subgrouping was considered appropriate.
The x2 test was then performed to detect associations
between RA and each SNP, with the entire test popu-
lation being used for the eight SNPs from unrelated genes
and with the subgrouped population being used for an
appropriate SNP(s).
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Table 2
PCR-ASO Primers and Conditions
SNP/GENE
CONTAINING
SNP
PCR PRIMER ASO-GENOTYPING PRIMER SPECIFIC TO
WASHING
TEMPERATURE
(C)
1 2 Major Allele Minor Allele
Major
Allele
Minor
Allele
rIL-3-16 GCCAGGGTAGTCCAGGTGAT CATTGAGGTTGTTGAAGTCC TTGGCAACAACCTCC GGAGGCTGTTGCCAA 50 50
cIL-3-131 GCCAGGGTAGTCCAGGTGAT CATTGAGGTTGTTGAAGTCC TTCAAGGACGTTGTC GACAACGCCCTTGAA 50 50
cGM-CSF-23 GAGTTCTAAGAGGCAGTAGAG TTCTTCTGCCATGCCTGTAT CCAGACTATCACC GTGATAATCTGGGT 35 49
MMP2 CCTGTGACCGAGAATGCGGAC CTCCTGGGAGTGCAGCCCAG GCGGACCCTCC AGGAGAGTCCGC 42 35
TNFR1 CTGTGTGGTTGTTTTCTGT GATGGGTGGGATGGATGGAC AGGAGAAGTGACC GGTCACCTCTCC 50 35
STAT6 CTAGTACAGGTTTTGCCCTG CTATGACCCCTGCCTTGGG CAGCTATACATTTAAC TTAAATATATAGCTGG 40 40
IL-15 GCAGAGAGGCTCATTGCTC CGGGAGCATAGGCGAAGAC GTTGGACTTCAAAG GTTGGACATCAAAG 35 49
IL-1b TGGTCTTGCAGGGTTGTGT CGTTGTGCAGTTGATGTCC GCTCCCGAGGCA TGCCTCAGGAGCT 38 38
CD44 AGATGGTTTCTCATAAGGTAAAA TATTGTGTGCAATCAGCCCTTT TGCTGTTACAATAATT AATTATTATAACAGCA 42 42
IL-4Ra TCCTCCTGCTGTTGCTATGA AAGAGTCTGATGCGGTTCCT TCAGGGACACACGTG CACGTGTATCCCTGA 53 53
TIMP1 GGAGTGGGAGGATTATGTCAGT CATTCCTCACAGCCAACAGT GCCTTTGGCAGC GCCTTTGCCAGC 42 35
Results
A. Data on rIL-3-16, cIL-3-131, and cGM-CSF-23
SNPs, for 254 Cases and 881 Controls
Demographic features and age-at-onset distribution
among subjects are summarized in tables 3 and 4. The
distribution of HLA-DRB1 types among our cases (table
5) was similar to that in a previous report from Japan
(Wakitani et al. 1997). Alleles and genotypes at the rIL-
3-16 marker are shown in table 6, along with allele and
genotype data on the control group, adjusted according
to sex and age distributions. The adjusted data on all
control groups deviated more from case data than did
nonadjusted control data, suggesting that nonadjust-
ed data are more conservative for detection of associa-
tion. Therefore, we used nonadjusted data for further
discussion.
An association between RA and SNP at rIL-3-16 was
statistically significant in a comparison of allele fre-
quencies in total cases versus with those in the controls
( ), as well as in a comparison of female casesPp .0002
versus female controls ( ) and in a compar-Pp .00002
ison of earlier-onset females versus female controls
( ) (table 7). Similar statistical significancePp .000004
was obtained with Fisher’s exact probability test; for
example, comparison of the allele frequencies in cases
versus those in all controls yielded a two-sided Fisher’s
exact probability of .0002. No statistical significance
was observed between subgroups of cases classified ac-
cording to rheumatoid-factor status, history of surgical
intervention(s), or RA-susceptible DRB1 status, regard-
less of sex ( ; data not shown). A comparison ofP 1 .3
male cases versus male controls provided no statistical
significance even after adjustment for age ( ).P 1 .95
Odds ratios with 95%CIs are shown in table 7. In the
comparison of total cases versus total controls, the odds
ratio of genotype TT (major-allele homozygotes) to CC
(minor-allele homozygotes) was 2.24 (95%CI 1.44–
3.49) and that of TC (heterozygotes) to CC was 1.50
(95%CI 0.98–2.30). When earlier-onset female cases
were compared with female controls, those ratios in-
creased to 7.27 (95%CI 2.8–18.89) and 3.8 (95%CI
1.48–9.79), respectively.
Allele and genotype frequencies of rIL-3-16, cIL-3-
131, and cGM-CSF-23 are shown in table 8. Almost-
identical genotype frequency was seen for cIL-3-131 and
rIL-3-16, suggesting that these two loci have the same
degree of association with RA. On the other hand, a
significant association with RA was not observed for the
cGM-CSF-23 SNP locus; this was especially true for the
frequency of major-allele homozygote, which showed
the strongest association with rIL-3-16. Our analyses of
LD, based on the estimated haplotypes of SNPs in the
IL-3 vicinity, are summarized in table 9. The rIL-3-16
and cIL-3-131 sites were in complete LD, and rIL-3-16
was linked to cGM-CSF-23 with D′ value of .78. No
particular haplotype showed higher statistical signifi-
cance for association with RA than did rIL-3-16 alone.
Hardy-Weinberg equilibrium of the distribution of gen-
otypes for each SNP, for both the case group and the
control group, was evaluated by x2 tests and showed no
significant deviation ( ; data not shown).P 1 .70
Thus far, P values have not been corrected for multiple
testing; however, even if Bonferroni’s correction were to
be applied, our result would still be statistically significant,
as is shown below. We did 21 comparisons (three types
of comparisons for each of seven pairs of comparison
groups): (1) total cases versus total controls, (2) total fe-
male cases versus total female controls, (3) total male cases
versus total male controls, (4) age-and-sex–adjusted cases
versus age-and-sex–adjusted controls, (5) HLA-DRB1–
positive group versus HLA-DRB1–negative group, (6)
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Table 3
Characterization of Cases and Controls
CASES CONTROLS
Overall Female Male Overall Female Male
No. 254 206 48 881 525 356
Fraction of sample:
Total .81 .19 .60 .40
Positive for:
Rheumatoid factor .81 .79 .88 … … …
History of surgical intervention(s) .47 .48 .41 … … …
RA-susceptible HLA-DRB1 typea .69 .68 .73 … … …
Average age (years):
At sampling 57.0 56.1 61.3 41.8 43.4 39.4
At onset 46.3 44.9 52.4 … … …
a Includes *0101, *0102, *0401, *0404, *0405, and *1001.
Table 4
Distribution of Ages at Onset of RA
AGE AT ONSET
(years)
FRACTION
Total
Sample Female Male
!30 .15 .17 .06
30–39 .18 .19 .09
40–49 .26 .25 .30
50–59 .20 .19 .24
60 .22 .20 .30
rheumatoid factor–positive group versus rheumatoid fac-
tor–negative group, and (7) history-of-surgical-interven-
tion(s)–positive group versus history-of-surgical-interven-
tion(s)–negative group, with all comparisons being done
for (i) one type of allele-frequency comparison and (ii)
two types of genotype-frequency comparison. Therefore,
when Bonferroni’s correction was applied, our most sig-
nificant P value—that is, .000004, for the comparison of
female cases versus total female controls—was corrected
to .0001, which is still significant.
B. IL-3 Promoter Assay
To investigate the possibility that rIL-3-16 SNP plays
a role in the promoter activity, we performed a lucif-
erase-activity assay, using two different lengths of ge-
nomic fragments with either of the SNP sequences. The
ratio of stimulated to unstimulated luciferase activity in
assays of the longer segment was 3.63 (SD 0.835) for
the T allele and 3.99 (SD 0.746) for the C allele, 48 h
after stimulation; the Student’s t value was 1.08 (Pp
). For the short-segment assay at 48 h, the ratios were.15
2.05 (SD 0.009) and 1.74 (SD 0.052) for the T and C
alleles, respectively; Student’s t value was 0.84 (Pp
)..22
C. Combinatorial Data on Two SNPs
We then investigated a combinatorial effect of two
SNPs: the rIL-3-16 and one SNP from a panel of eight
other candidate genes. The results of x2 tests for asso-
ciations between SNPs in the eight different genes and
RA and between rIL-3-16 and RA, as well as the results
of maximum-likelihood estimation of relationships be-
tween those eight SNPs and rIL-3-16, are shown in table
10. The x2 values listed in this table were the largest
ones observed among comparisons of genotype fre-
quencies for each SNP. The SNPs on the IL-1b, CD44,
and TNFR1 genes were considered to have combina-
torial effects with IL-3 genotype status, in contributing
to RA. The IL-4Ra gene had the same LOD scores for
independent and combinatorial patterns, and the other
four genes were estimated to be independent of rIL-3-
16’s genotype status. Of the three genes that appeared
to have combinatorial effects with rIL-3-16, IL-1b
yielded the largest difference, 0.8 ( ), betweenPp .1
LOD scores of combinatorial and independent patterns.
rIL-3-16 and IL-1b were further assessed for combina-
torial effect and association with RA, with the subdi-
vided population.
Our estimates of relative risk for RA with respect to
alleles of rIL-3-16 and of the IL-1b gene were as follows:
compared with homozygotes for nondisease alleles of
both SNPs, homozygotes for disease alleles of both SNPs
carried a relative risk of 5.3, whereas persons homo-
zygous for the disease allele of one SNP and heterozy-
gous for the other would carry a relative risk of 2.3;
relative risk for heterozygotes for both SNPs were 1.5,
and that for the rest was 1.0 (Appendix, pattern 6). This
pattern represents the situation in which a disease-sus-
ceptible allele of either gene requires the other gene’s
disease allele in order to produce its own effect and in
which the relative risk for persons homozygous for the
disease allele of either SNP is the square of that for
heterozygotes. Because pattern 6 was estimated as being
most likely, the subgroup of patients with RA who car-
ried either the TT or the TC genotype of rIL-3-16 was
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Table 5
Distribution of HLA DRB1 Types of among Japanese Patients
with RA
HLA-DRB1
FRACTION
Patients with RA
Controls Reported by
Wakitani et al. (1997)
Present
Study
Wakitani
et al. (1997)
*0101 .114 .144 .084
*0102 .000 … …
*0401 .081 .047 .025
*0404 .016 .005 .000
*0405 .526 .499 .290
*1001 .031 .018 .012
Table 6
Allele and Genotype Data on rIL-3-16 TrC
ALLELE GENOTYPE
OVERALL
Major
(T)
Minor
(C)
Major
Homozygotes
(TT)
Heterozygotes
(TC)
Minor
Homozygotes
(CC)
Cases:
Total:
No. (female/male) 323 (270/53) 185 (142/43) 101 (86/15) 121 (98/23) 32 (22/10) 254 (206/48)
Fraction (female/male) .64 (.66/.55) .36 (.34/.45) .40 (.42/.31) .48 (.48/.48) .13 (.11/.21)
Age at onset !55 years:
No. (female/male) 167 (146/21) 75 (60/15) 55 (48/7) 57 (50/7) 9 (5/4) 121 (103/18)
Fraction (female/male) .69 (.70/.58) .31 (.29/.42) .45 (.47/.39) .47 (.49/.39) .07 (.05/.22)
Controls:
Total:
No. (female/male) 954 (559/395) 808 (491/317) 252 (140/112) 450 (279/171) 179 (106/73) 881 (525/356)
Fraction (female/male) .54 (.53/.55) .46 (.47/.45) .29 (.27/.31) .51 (.53/.48) .20 (.20/.21)
Sex adjusted:
No. (female/male) 907 (731/176) 855 (699/156) 221 (177/44) 465 (377/88) 195 (161/34) 881 (715/166)
Fraction (female/male) .51 (.51/.53) .49 (.49/.47) .25 (.25/.27) .53 (.53/.53) .22 (.23/.21)
selected for further tests of association between the SNP
on IL-1b and RA, and the subgroup of those either ho-
mozygous or heterozygous for the disease allele of the
SNP on IL-1a was selected for testing of association
between rIL-3-16 and RA. Eighty-six cases and 72 con-
trols constituted the subgroup of those either homozy-
gous or heterozygous for the disease allele of the SNP
on IL-3, and 67 cases and 54 controls constituted the
subgroup either homozygous or heterozygous for the
disease allele of the SNP on IL-1b. The results are shown
in table 11. For rIL-3-16 and the SNP on IL-1b, the
statistical significance of associations with RA when
these selected subgroups were used were 110 times and
14 times stronger, respectively, than values obtained with
association tests comparing 91 cases versus 91 controls.
Discussion
We have reported here a significant association between
a CrT substitution at the 16 position of the IL-3 gene
and RA. Although our control group consisted of 3.5
times as many individuals as were in the RA group,
application of x2 tests was statistically appropriate, be-
cause similar results were obtained with Fisher’s exact-
probability test. Since we intended for the control group
to represent the general Japanese population without
RA, the distributions of sex and age in the two groups
were not the same. However, it seemed clear that sex
differences and age differences between the case group
and the control group had no significant influence on
the statistical analyses, because association tests per-
formed with sex- or age-adjusted controls revealed an
even more significant association than was revealed by
association tests using the data for control individuals
as a whole.
Comparisons between each of the subgroups cate-
gorized by female sex and/or earlier onset disclosed
strong associations that became even more significant
when females with earlier-onset RA were compared
with sex- and age-matched controls and with the overall
sample of controls. On the other hand, in the male
population, no association was observed between the
SNP and RA. It seemed that the SNP was associated
with RA in females, particularly with females with ear-
lier-onset RA. This result is consistent with epidemio-
logical data indicating that females with earlier-onset
RA constitute a distinct subgroup among the total RA
population and that, at ages up to the mid-50s, females
are more susceptible to RA than are males (Ehrlich et
al. 1970; Deal et al. 1985). IL-3 and some other factor(s)
specific to reproductive females may have synergistic
effects for increasing the risk for RA. This finding is
very interesting because it may help to differentiate pa-
tients with RA into subgroups with different genetic
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Table 7
Tests for Association and Odds Ratios, for Genotype Data Regarding the rIL-3-16 Locus
GROUPS COMPARED
TEST OF ASSOCIATION
(x2 a [P] ) ODDS RATIO [95%CI]
Allele Frequency
(Major Allele
vs. Minor Allele)
Genotype
Frequency
(2#3 table)
Major
Homozygotes:
Others
Minor
Homozygotes:
Others
Heterozygotes:Minor
Homozygotes
Major:Minor
Homozygotes
Cases vs. controls 14.28 [.0002] 14.88 [.0006] 11.46 [.0007] 7.76 [.005] 1.50 [0.98–2.30] 2.24 [1.44–3.49]
Female cases vs. female controls 18.22 [.00002] 19.42 [.00006] 15.75 [.00007] 9.27 [.002] 1.69 [1.01–2.83] 2.96 [1.74–5.04]
Male cases vs. male controls .003 [1.0] .003 [1.0] .0009 [1.0] .0003 [1.0] .98 [0.45–2.17] .98 [0.42–2.29]
Earlier-onset cases vs. controls 19.08 [.00001] 19.60 [.00006] 14.21 [.0002] 11.58 [.0007] 2.52 [1.22–5.20] 4.34 [2.09–9.01]
Earlier-onset female cases vs. female controls 21.75 [.000004] 23.24 [.000009] 16.32 [.00005] 13.92 [.0002] 3.80 [1.48–9.79] 7.27 [2.80–18.89]
a For x2 values for genotype frequency (2#3 tables), df p2; for the other x2 values, df p1.
Table 8
Allele and Genotype Frequencies of rIL-3-16, cIL-3-131, and cGM-CSF-23
FREQUENCY
Allele Genotype
Major Minor
Major
Homozygotes Heterozygotes
Minor
Homozygotes
Cases:
rIL-3-16 .64 .36 .40 .48 .13
cIL-3-131 .64 .36 .40 .48 .13
cGM-CSF-23 .66 .34 .41 .49 .11
Controls:
rIL-3-16 .55 .45 .29 .51 .20
cIL-3-131 .55 .45 .29 .52 .19
cGM-CSF-23 .61 .39 .39 .43 .18
backgrounds. Other conditions, including rheumatoid-
factor status, history of orthopedic surgical interven-
tion, or HLA-DRB1 status, appeared to have no rela-
tionship to the effect that IL-3 has on RA; in our
experience, the latter association seemed to be, to some
extent, independent of HLA-DRB1 and did not exert
much influence on either the production of rheumatoid
factor or the destructive activity of RA. It is worth not-
ing, too, that the SNP on GM-CSF, the gene lying closest
to the IL-3 gene, retained no statistically significant as-
sociation with disease status, although LD between the
two loci was substantial. The rIL-3-16 and cIL-3-131
SNPs, which are in complete LD, might be causative
genetic variations—or, at least, might be in closer prox-
imity to a causative genetic alteration than is cGM-CSF-
23. Our results support a previous report of association
between IL-3 and RA (Heller et al. 1997) and do not
contradict two published sib-pair linkage studies of RA
(Cornelis et al. 1998; Shiozawa et al. 1998), both of
which reported LOD scores close to 2, for D5S422 on
5q32-33. That LOD score is not large enough to allow
conclusive identification of a disease locus for RA, but
it nonetheless provides evidence supporting our results.
In the Results section, we have shown, for the most
significant association, the P value corrected with Bon-
ferroni’s correction; however, we have not used Bon-
ferroni’s correction for the other P values, because we
believe that it would produce a P value that would be
too conservative for assessment of our data. The reasons
why we believe that Bonferroni’s correction would pro-
duce a P value that is too conservative are as follows:
(1) we decided to be conservative by avoiding the
strongest association found in comparisons between
age-sex adjusted groups, and (2) a trend of increase, in
association, to explain specific association of a distinct
clinical entity and the SNP made our multiple compar-
isons nonrandom.
With regard to complex genetic traits, each related
gene contributes disease susceptibility to some extent,
but such genes may also interact with each other. There-
fore, in addition to undertaking large-scale, multilocus
genotyping studies for identification of genes associated
with a multifactorial disease, one must identify loci
making small contributions and dissect relationships be-
tween multiple loci. However, it is not easy to estimate
the interaction of loci, each of which may have only a
small effect on disease susceptibility. In the study re-
ported here, we divided cases into subgroups based on
sex, age at onset, HLA-DRB1 status, rheumatoid-factor
status, and requirement for surgical intervention(s),
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Table 9
Haplotype-Frequency Estimation and LD, for rIL-3 16-cIL-3 131
and rIL-3 16-cGM-CSF 23
GROUP FREQUENCY OF HAPLOTYPE D′
T-T C-C T-C C-T
rIL-3 16-cIL-3 131:
Cases ( )np 254 .6339 .3642 .0020 .0000 1.00
Controls ( )np 130 .5577 .4423 .0000 .0000 1.00
Total ( )np 384 .6081 .3906 .0013 .0000 1.00
T-C C-T C-C T-T
rIL-3 16-cGM-CSF 23:
Cases ( )np 84 .6050 .3074 .0438 .0438 .81
Controls ( )np 91 .4999 .3351 .1100 .0550 .75
Total ( )np 175 .5504 .3218 .0782 .0496 .78
Table 10
Results of x2 Tests for Association between SNPs in Nine Genes and RA, and Estimation of Relationships
between Eight SNPs and rIL-3-16
GENE CONTAINING SNP
ASSOCIATION TEST OF 91
CASES OF RA VS. 91 CONTROLS
(x2 a [P])
LOD SCOREb
Combinatorial
Pattern
Independent
Pattern Difference
MMP2 1.93 [.16] 1.7 1.8 .1
TNFR1 1.99 [.16] 1.9 1.6 .3
STAT6 2.23 [.14] 1.6 1.7 .1
IL15 2.58 [.11] 1.7 1.8 .1
IL-1b 2.91 [.09] 2.8 2.0 .8
CD44 3.92 [.05] 3.4 2.8 .6
IL-4Ra 4.85 [.03] 2.4 2.4 .0
TIMP1 5.30 [.02] 3.3 3.4 -.1
IL-3 (rIL-3-16) 5.67 [.02] … … …
a Maximum value, among comparisons of genotype frequencies.
b Under hypothesis that no association exists between two SNPs and RA.
since previous studies had suggested that these param-
eters are appropriate for the subgrouping of patients
with RA (Gordon and Hastings 1994; Selden et al.
1999). Before we apply genotype data to the effort to
subdivide populations for association tests using SNPs
in multiple genes, the subgrouping procedure should be
justified. For justification of our analyses, we applied
two hypotheses to estimate a relationship between any
two SNPs; the first hypothesis speculated that there is
a functional relationship between two genes, and the
other hypothesis justified the use of subdivided popu-
lations by expecting that genotype information for one
SNP would strengthen our power to detect other as-
sociated loci. The maximum difference between LOD
scores for independent patterns and LOD scores for
combinatorial patterns was 0.8, for the relationship be-
tween IL-3 and IL-1b. Statistical significance should be
obtained by approximating a distribution of a doubled
value of the difference between LOD scores, to a 50:50
mixture of a x2distribution with 1 df and a probability
mass at 0, because, in the number of variables used, the
difference between independent and combinatorial
models was 1 and because, to maintain the intensity of
relative risk of homozygosity of the susceptibility allele,
heterozygosity, and homozygosity of the nonsuscepti-
bility allele, in this order, significance was declared in
one direction. The P value for the 0.8 difference between
LOD scores is .1, which is not statistically significant.
The reason why statistical significance is not large is
that the sample size that we used for our preliminary
estimation is small. However, sample size should be
larger for future studies, to evaluate relationship among
genes. Therefore, statistical significance has been sim-
ulated for larger sample sizes, as is shown below; for
example, if, instead of 91, the sample size were 1,000,
for both the case group and the control group, and if
the same genotype frequency were obtained as was seen
in our preliminary observation of IL-3 and IL-1b, then
the difference between LOD scores would be 8.8 instead
of 0.8, and the P value would be .000014, which would
seem to be significant enough to justify subgrouping.
The effect that the use of subdivided populations has
on tests of association has been assessed as described
below. As shown in table 10, in the tests for association
with RA that do not use subdivided population, IL-1b
shows a smaller x2 value than does either IL-4Ra or
TIMP1. In the estimation of its relationship with IL-3,
IL-1b showed larger LOD scores than did either IL-4Ra
or TIMP1. When the subdivided population was used,
the x2 value in the test for association with RA increased
from 2.91 to 5.37. The increased value, 5.37, was more
than the x2 value for IL-4Ra, 4.85, and was closer to
that of TIMP1, 5.30. This change suggests that the es-
timation may be useful in screening for modifier genes
that, by themselves, do not affect the pathogenesis of
the disease strongly enough to be identified by exami-
nation of the association between a disease and a single
gene. In addition, the relationship between IL-3 and IL-
682 Am. J. Hum. Genet. 68:674–685, 2001
Table 11
Association between SNPs in either IL-3 or IL-1b
and RA, for the Entire Sample and Selected
Subgroups
GENE CONTAINING SNP
ASSOCIATION WITH RA
(x2 [P])
Entire
Sample
Selected
Subsamples
IL-3 5.67 [.02] 10.01 [.002]
IL-1b 2.91 [.09] 5.37 [.02]
1b has been supported by biological studies. IL-1b has
been reported to up-regulate IL-3 in the mast cell (Hult-
ner 2000), suggesting that, in combination, the SNP
causing amino acid substitution in the IL-1b gene and
the SNP in the promoter region of IL-3 may affect the
expression level of IL-3. IL-1b and IL-3 also have been
shown to regulate hyaluronan binding to the monocyte
CD44 molecule, a key event in the initiation of inflam-
mation (Levesque and Haynes 1997). These biological
observations, combined with our preliminary genetic
estimation, indicate that there is a network including
these three molecules that regulates inflammation and
that the change of this network by these SNPs will be
one of the main events in the pathogenesis of RA.
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Appendix
Relative Risk of Genotypes
Posit SNP A and SNP B, which are not linked phys-
ically. Disease-susceptibility alleles of SNP A and B are
denoted as “a1” and “b1,” and nonsusceptibility alleles
are denoted as “a2” and “b2.” Let Gijkl be the relative
risk of genotype aiajbkbl, compared with the risk of ge-
notype a2a2b2b2, when each of i, j, k, and l is either 1
or 2.
Define Gijkl by five parameters—G, r1, r2, r3, and r4
( , , .5, 1):G 1 1 r p 0i
G p G1111
r1G p G1112
r1#r2G p G1122
r3G p G1211
r1#r3G p G1212
r1#r2#r3G p G1222
r3#r4G p G2211
r1#r3#r4G p G2212
G p 12222
Arrange Gijkl in a 3#3 matrix:
G G G1111 1112 1122
G G G1211 1212 1222
G G 12211 2212
By this definition, distribution patterns of relative risk
are modeled as below. Note that g takes either G or the
square root of G, as defined above.
Pattern 1—heterozygosity or homozygosity of suscep-
tibility allele of either SNP is adequate to raise risk:
g g g
g g g
g g 1
Pattern 2—heterozygosity or homozygosity of suscep-
tibility allele of SNP A is necessary to raise risk:
g g g
g g g
1 1 1
Pattern 3—homozygosity of susceptibility allele of SNP
A is necessary to raise risk:
g g g
1 1 1
1 1 1
Pattern 4—heterozygosity or homozygosity of suscep-
tibility allele of SNP B is necessary to raise risk:
g g 1
g g 1
g g 1
Pattern 5—homozygosity of susceptibility allele of one
SNP B is necessary to raise risk:
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g 1 1
g 1 1
g 1 1
Pattern 6—heterozygosity or homozygosity of suscep-
tibility allele of both SNPs is necessary to raise risk:
g g 1
g g 1
1 1 1
Pattern 7—heterozygosity or homozygosity of suscep-
tibility allele of SNP A and homozygosity of suscepti-
bility allele of SNP B are necessary to raise risk:
g 1 1
g 1 1
1 1 1
Pattern 8—homozygosity of susceptibility allele of SNP
A and heterozygosity or homozygosity of susceptibility
allele of SNP B is necessary to raise risk:
g g 1
1 1 1
1 1 1
Pattern 9—homozygosity of susceptibility allele of both
SNPs is necessary to raise risk:
g 1 1
1 1 1
1 1 1
One more important relationship, not modeled in the
equations above, was that in which two loci contribute
independently, regardless of the partner gene’s genotype
status. For this relationship, we introduced a different
definition: parameters ga and gb represent a homozy-
gote’s relative risk of SNP A and SNP B, respectively.
Assume parameters fa and fb to be 0, .5, or 1, to control
the heterozygote’s relative risk according to ga and gb.
Independent Pattern of Genotypes
G p g # g1111 a b
fbG p g # g1112 a b
G p g1122 a
faG p g # g1211 a b
f fa bG p g # g1212 a b
faG p g1222 a
G p g2211 b
fbG p g2212 b
G p 12222
Proportion of Genotypes among Population and Case
or Control Group
The test population was in Hardy-Weinberg equilib-
rium. Disease prevalence d was extrapolated from epi-
demiological studies; in our text, we have assumed that
for RA. Frequencies of disease-susceptibility al-dp .01
leles of either SNP A or SNP B are pa or pb, respectively.
Let , , and denote a proportion ofP C Na a b b a a b b a a b bi j k l i j k l i j k l
people with genotype aiajbkbl, in the whole population,
in the case population, and in the control population,
respectively. The following equalities are present:
P p p # p # p # pa a b b a a b b1 1 1 1
P p p # p # 2# p # (1 p )a a b b a a b b1 1 1 2
P p p # p # (1 p )# (1 p )a a b b a a b b1 1 2 2
P p 2# p # (1 p )# p # pa a b b a a b b1 2 1 1
P p 2# p # (1 p )# 2# p # (1 p )a a b b a a b b1 2 1 2
P p 2# p # (1 p )# (1 p )# (1 p )a a b b a a b b1 2 2 2
P p (1 p )# (1 p )# p # pa a b b a a b b2 2 1 1
P p (1 p )# (1 p )# 2# p # (1 p )a a b b a a b b2 2 1 2
P p (1 p )# (1 p )# (1 p )# (1 p )a a b b a a b b2 2 2 2
P p C Na a b b a a b b a a b bi j k l i j k l i j k l
SP p 1a a b bi j k l
SC p da a b bi j k l
SN p 1 da a b bi j k l
(C # Pa a b b )/(C # P )p Ga a b b 2 2 2 2 a a b b a a b b a a b bi j k l 2 2 2 2 i j k l i j k l
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Maximum-Likelihood Model and Likelihood Ratio
Consider a random case-control sampling from A suf-
ficiently large population; that is, on in which sampling
an individual would not affect conditions of successive
sampling. Let and denote the observedQ Ra a b b a a b bi j k l i j k l
data on cases and controls, respectively, with genotype
aiajbkbl. The conditional probabilities for sampling a case
and a control with genotype aiajbkbl are, respectively,
and . Then the logarithm of like-C /d N /(1 d)a a b b a a b bi j k l i j k l
lihood (L) of the observed data is
Lp S[Q # log(C /d)]a a b b a a b bi j k l i j k l
log[(SQ )!] S{log[(Q )!]}a a b b a a b bi j k l i j k l
S[R # log[N /(1-d)]a a b b a a b bi j k l i j k l
log([SR )!] S{log[(R )!]} .a a b b a a b bi j k l i j k l
The most likely estimate of parameters is obtained,
and the most-fit pattern of relative-risk distribution is
estimated by comparison of the values of L.
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